Elevated parathyroid hormone (PTH) levels have been associated with increased cardiovascular risk in the general population. We aimed to elucidate whether PTH levels are associated with mortality and fatal cardiovascular events in patients referred for coronary angiography.
Introduction
Parathyroid hormone (PTH), which is crucial for the maintenance of calcium homeostasis, has been associated with increased cardiovascular risk. 1 Parathyroid hormone is secreted by the parathyroid glands in response to hypocalcaemia which is detected by the calcium sensing receptor (CaSR). 2 Classic PTH effects on bone and kidney are important for the control of calcium homeostasis, but PTH receptors are also expressed in the vessel walls and the myocardium suggesting direct effects on the cardiovascular system. 1 In this context, PTH levels have been associated with hypertension, myocardial dysfunction, and vascular diseases. 1 -6 Primary hyperparathyroidism, characterized by inadequately high PTH levels with subsequent hypercalcaemia, has been associated with increased cardiovascular risk and mortality, which could be significantly reduced by parathyroidectomy in most but not all studies in this field. 1, 2, 7 Secondary hyperparathyroidism, which is frequently observed in patients with impaired kidney function, is also associated with increased mortality and PTH modifying therapies have been shown to improve the clinical outcome of patients with renal failure. 2, 8 Only a few studies addressed the clinical significance of PTH levels for mortality and cardiovascular diseases in persons without significant renal disease. 2, 7 Currently available studies in this field have shown an association of PTH levels and mortality in the elderly. 2,9 -15 Importantly, a recent study among a community-based cohort of 958 elderly men has shown that PTH levels within the normal range are predictive for fatal cardiovascular events. 13 Whether this applies for both genders and for patients at higher cardiovascular risk remains largely unknown. Given that PTH modifying therapies such as vitamin D and calcium supplementation can be easily and relatively safely performed, there exists a great public health interest to elucidate whether PTH is a promising target for the treatment to reduce cardiovascular risk. 1,2 Hence, we aimed to prospectively evaluate whether PTH levels are a risk factor for mortality and fatal cardiovascular events [e.g. sudden cardiac death (SCD)] in a large cohort of patients referred for coronary angiography.
Methods

Participants and study design
The LURIC study, a prospective cohort study of patients referred to coronary angiography, was designed to investigate environmental and genetic risk factors for cardiovascular diseases. 16 The baseline examination was performed between July 1997 and January 2000 at a tertiary care centre in south-west Germany (Herzzentrum Ludwigshafen) and included 3316 study participants. Inclusion criteria were the availability of a coronary angiogram, clinical stability with the exception of acute coronary syndromes (ACSs), and Caucasian origin, in order to limit genetic heterogeneity. Indications for coronary angiography were commonly chest pain or non-invasive tests in which myocardial ischaemia was suspected. Patients with any acute illness other than ACS, with a history of malignancy within the past 5 years and with any predominant non-cardiac disease were excluded from the study. Informed written consent was obtained from all study participants and approval for the study was obtained from the ethics committee at the 'Ä rztekammer Rheinland-Pfalz' (Mainz, Germany). The LURIC study complies with the Declaration of Helsinki.
Baseline examination
Detailed descriptions of the baseline examination in LURIC have been published previously. 16 Angiographic coronary artery disease (CAD) was diagnosed in patients with at least one stenosis ≥50% of at least one out of 15 coronary segments, using the maximal luminal narrowing estimated by visual analysis. Diabetes mellitus was diagnosed if the fasting glucose was .7.0 mmol/L or the 2 h value in an oral glucose tolerance test was .11.1 mmol/L and in patients already receiving antidiabetic medication. Arterial hypertension was diagnosed if the mean systolic and diastolic blood pressures out of five measurements exceeded 140 and/or 90 mmHg or if patients were already on antihypertensive treatment.
Biochemical analyses
Routine laboratory measurements were performed as previously described. 16 In brief, venous blood sampling was performed in the morning before coronary angiography and routine laboratory parameters were immediately determined, whereas remaining blood samples were snap frozen for further determinations and stored at 2808C until analysis. Intact PTH was determined in serum by ), LDL-and HDL-cholesterol (mg/dL), triglycerides (mg/dL), C-reactive protein (mg/L), ex-and active smokers (yes/no), and number of diseased vessels (0 -3 vessels). In addition to the covariates of Model 2, we adjusted for the use of medication (ACE-inhibitors, beta-blockers, diuretics, aspirin/other antiplatelet agent, and statins), ventricular dysfunction (NT-pro-BNP) (ng/mL), markers of malnutrition (haemoglobin in g/dL and albumin in g/dL), serum calcium (mmol/L), or 25(OH)D (ng/mL). A further model (Model 3) included all covariates of Model 2 plus various parameters of mineral metabolism (serum calcium, serum phosphate, 25 [OH]D, and use of diuretics). We also calculated HRs for patients within the reference range of PTH (≤65 pg/mL) to test whether our findings also apply for individuals without hyperparathyroidism. In addition, we tested for interactions by adding product terms to the multivariable adjusted models (Model 2) in order to examine whether the association of PTH quartiles with mortality differs according to sex and the presence or absence of ACS, CAD, significant renal failure (defined as GFR ≤ 60 mL/min/1.73 m 2 ), or vitamin D deficiency (defined as 25 [OH]D below 20 ng/mL). Finally, we calculated the C statistic (equivalent to the area under the receiver operating characteristic curve) to assess the discriminative power of the multivariate adjusted model (Model 2) with and without PTH. A P-value , 0.05 was considered statistically significant and all statistical tests were two-sided. Data were analysed using SPSS 15.0 statistical package (SPSS Inc., Chicago, IL, USA).
Results
Parathyroid hormone levels were available in 3232 study participants and elevated PTH levels above 65 pg/mL which are indicative for hyperparathyroidism were observed in 174 patients (5.4%).
Only three patients with hyperparathyroidism displayed hypercalcaemia, defined as serum calcium levels above 2.65 mmol/L, indicative for primary hyperparathyroidism. Clinical and laboratory baseline characteristics according to PTH quartiles are shown in Table 1 . Coronary artery disease was ruled out in approximately one-third (31.9%) of the study population. Age, BMI, blood pressure, C-reactive protein, aldosterone, and NT-pro-BNP were significantly increased and triglycerides, GFR, haemoglobin, albumin, 25(OH)D, 1,25 (OH)2D, serum calcium, and serum phosphate were significantly decreased in higher PTH quartiles. Proportion of ex-and active smokers, patients with ACS, and use of beta-blockers were significantly reduced and females, higher NYHA classes, frequency of atrial fibrillation and ACS, and the use of ACE-inhibitors and diuretics were significantly increased in patients with higher PTH quartiles.
Parathyroid hormone, mortality, and fatal cardiovascular events
Eighteen patients were lost during a median follow-up time of 7.7 years (interquartile range: 7.2 -8.5 years) and in 24 study participants we did not obtain sufficient information to classify their causes of death. These latter patients were included in the analyses for all-cause mortality but excluded from analyses for cardiovascular mortality and specific cardiovascular events. Among 3232 patients with available PTH levels, 742 died during follow-up, of whom 467 died due to cardiovascular causes. Among specific cardiovascular events we recorded 187 SCDs, 84 fatal myocardial infarctions, 112 deaths due to heart failure, and 84 deaths due to other cardiovascular causes. Kaplan -Meier curves followed by a log-rank test showed that all-cause and cardiovascular mortality significantly increased in the highest two PTH quartiles (P , 0.001 for both; Figure 1A and B). association with the lowest mortality risk in the second PTH quartile and a significantly increased mortality risk in the third PTH quartile and even more pronounced in the fourth PTH quartile. Unadjusted HRs (with 95% CI) for all-cause and cardiovascular mortality in the fourth (highest) PTH quartile when compared with the first (lowest) PTH quartile were 2.13 (1.75-2.60) and 2.47 (1.92-3.17), respectively ( Table 2) . After adjustments for common cardiovascular risk factors, these HRs were attenuated to 1.71 (1.39-2.10) for all-cause mortality and 2.02 (1.55-2.63) for cardiovascular mortality. These HRs remained significant even after further adjustments for the use of medication, NT-pro-BNP, albumin and haemoglobin, serum calcium, 25(OH)D, or a combination of various parameters of mineral metabolism ( Table 2) . Adjustments for albumin-corrected serum calcium or aldosterone did also not materially change our results (data not shown). For allcause mortality, the C statistic for Model 2 was 0.759 (95% CI: 0.739-0.778) without PTH and 0.765 (0.746-0.785) with PTH. For cardiovascular mortality, the C statistic was 0.748 (0.724 -0.771) without PTH and 0.758 (0.734-0.782) with PTH.
After exclusion of patients with hyperparathyroidism defined as PTH levels above 65 pg/mL, the HRs in the fourth vs. the first PTH quartile remained significant for all-cause [ Table 2 ).
In analyses for all-cause mortality, there were no significant interactions of PTH quartiles with ACS (P ¼ 0.408), CAD (P ¼ 0.597), significant renal disease (P ¼ 0.259), and vitamin D deficiency (P ¼ 0.289). In subgroup analyses, adjusted HRs for allcause mortality (according to Model 2 in Table 2 ) in the fourth vs. the first PTH quartile were 1.87 (1.30-2.67) for patients with ACS (n ¼ 1003), 1.61 (1.25-2.08) for patients without ACS (n ¼ 2229), and 1.69 (1.25-2.29) for patients with stable CAD (no ACS but CAD; n ¼ 1248). For further adjusted HRs of the respective subgroup analyses see Figure 2A . In analyses for cardiovascular mortality, there were also no significant interactions of PTH quartiles with ACS (P ¼ 0.990), CAD (P ¼ 0.622), significant renal disease (P ¼ 0.304), and vitamin D deficiency (P ¼ 0.460). In subgroup analyses, adjusted HRs for cardiovascular mortality in the fourth vs. the first PTH quartile were 2.04 (1.48-2.81) for patients with ACS, 1.91 (1.20-3.06) for patients without ACS, and 2.01 (1.39-2.90) for patients with stable CAD. For further adjusted HRs of the respective subgroup analyses see Figure 2B .
In analyses of the entire study cohort for specific cardiovascular events, the HR adjusted (Model 2 in Table 2 ) for common cardiovascular risk factors in the fourth vs. the first PTH quartile was 2.68 (1.71-4.22) for SCD, 1.85 (1.02-3.35) for fatal myocardial infarction, and 1.94 (1.15-3.25) for deaths due to heart failure.
All of our results did not materially change, when males and females were analysed separately and there was no significant interaction by sex for the association of PTH quartiles with all-cause mortality (P ¼ 0.842) and cardiovascular mortality (P ¼ 0.965).
Discussion
In patients referred to coronary angiography, PTH levels were significantly associated with all-cause and cardiovascular mortality. These results remained significant after adjustments for common cardiovascular risk factors and other possible confounders including parameters of mineral metabolism. Our findings were materially unchanged after excluding patients with hyperparathyroidism and the association of PTH with mortality was not significantly different in patients with or without CAD, ACS, significant renal disease, or vitamin D deficiency. Among specific cardiovascular events, we observed a particularly strong association of PTH with SCD.
Our findings are in line with other studies which found an association of PTH and increased mortality. 2,8 -15 However, we are, to the best of our knowledge, the first to show (i) that PTH is associated with all-cause and cardiovascular mortality in a large cohort of patients referred to coronary angiography and (ii) that PTH is an independent risk factor for SCD. 2,8 -15 Given this strong association of PTH and cardiovascular risk in epidemiological studies, it could be hypothesized that PTH itself contributes to vascular and myocardial diseases. This notion is supported by the fact that vascular smooth muscle cells, endothelial cells, and cardiomyocytes are all target cells for PTH. 1, 21 Clinical studies showing associations of PTH levels or primary hyperparathyroidism with endothelial dysfunction, coronary heart disease, and carotid-intima media thickness suggest however, be acknowledged that the underlying mechanism for these pro-atherosclerotic effects of PTH remain largely unknown. An association of PTH levels with atherosclerosis was not consistently observed in all studies, 1,2,22 including our study which failed to show a significant association of PTH levels and angiographic CAD ( Table 1) . Another proposed mechanism linking PTH to cardiovascular diseases may be arterial hypertension because PTH infusions increased blood pressure in healthy volunteers and PTH was an independent determinant of blood pressure in a population-based study. 1, 3, 23 We also observed an association of PTH levels with elevated blood pressure in the LURIC study. After controlling for blood pressure and use of antihypertensive medication, the association of PTH with increased cardiovascular risk remained significant suggesting other mechanisms than hypertension mediating the relationship of PTH levels and fatal cardiovascular events.
Direct effects of PTH on cardiomyocytes may be mechanistically relevant for our mortality results because PTH induces myocardial hypertrophy, increases heart rate and automaticity, and may thus increase the risk of cardiac arrhythmias and fatal cardiovascular events. 24, 25 In line with this, McCarty et al. 24 hypothesized that PTH-induced activation of phospholipase C (PLC) may increase arrhythmias by generation of inositol-1,4,5-triphosphate, which has been associated with reperfusion arrhythmias, likewise by increasing calcium release from the sarcoplasmatic reticulum. The association of PTH with atrial fibrillation and SCD in the LURIC study fits well to the concept that PTH increases the risk for arrhythmias. Apart from this, we observed an association of PTH with NT-pro-BNP and higher NYHA class suggesting a link between PTH and heart failure. This is consistent with studies showing that PTH levels are increased in patients with heart failure and are an independent predictor of hospitalization for heart failure. heart failure, it was speculated that elevated PTH levels contribute to a systemic illness that accompanies heart failure and is characterized by increased oxidative stress, a pro-inflammatory state with elevated IL-6 and TNF-a levels and a catabolic state. 26, 28 It should, however, be noted that increases in PTH in patients with heart failure are often simply a consequence of increased urinary calcium loss due to both the use of diuretics and secondary hyperaldosteronism. 28 Furthermore, there is evidence that PTH exerts inotropic effects and improves contractile performance of cardiomyocytes. 1, 29 Hence, the association of PTH with heart failure is a complex interplay of various harmful and beneficial PTH effects on myocardial structure and function that need to be further clarified in detail. Given the relatively strong and independent association of PTH with increased risk of mortality and fatal cardiovascular events, we believe that further studies are needed to elucidate whether PTH modifying therapies such as vitamin D supplementation, calcium intake, or treatment with calcimimetics (CaSR agonists) improve the clinical outcome of patients at high cardiovascular risk and with elevated or high normal PTH levels. In our opinion, in particular, vitamin D supplementation is a promising therapeutic approach. Apart from lowering PTH levels, vitamin D is suggested to exert numerous beneficial effects on the cardiovascular system, prevents fractures and falls, and may reduce other diseases such as infections and cancer. 17,30 -33 Importantly, treatment of secondary hyperparathyroidism has already been shown to improve the clinical outcome of patients with renal failure. 2 We are aware that in the LURIC study, GFR decreased with higher PTH quartiles suggesting beginning (renal) secondary hyperparathyroidism, but our results remained materially unchanged after adjustment for GFR. Importantly, our data suggest that PTH is a risk factor for cardiovascular diseases in both patients with and without significant renal disease (Figure 2A and B) . A limitation of the present work is that our results apply only to carefully selected patients undergoing coronary angiography and without predominant non-cardiac disease or malignancy. Our findings may therefore not be generalizable. Furthermore, despite careful adjustments for several possible confounders we cannot rule out residual confounding. On the other hand, our statistical models may also be over-adjusted because some covariates might lie in the causal pathway of deleterious PTH effects. Another drawback of our work is that we did not measure both parathyroid hormone-related peptide (PTH-rP), 21 a structuralrelated peptide which shares some effects with PTH, as well as fibroblast growth factor-23 (FGF-23), which predicts mortality and prevents hyperphosphataemia by suppressing PTH and 1,25-dihydroxyvitamin D. 34, 35 In summary, we have shown that PTH even within the normal range is associated with mortality and fatal cardiovascular events in patients undergoing coronary angiography.
Further studies are needed to elucidate the underlying mechanisms for our results and to evaluate whether PTH modifying therapies reduce cardiovascular risk.
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